Royalty Pharma: A Lower-Risk Approach to Investing in Biotechnology

Royalty Pharma is a biotech financier that provides large upfront cash payments to drug developers in exchange for future royalties on their medicines. The company has a diversified portfolio of over 35 revenue-generating therapies and has recently deployed nearly $1.3 billion across two major deals and raised an additional $2 billion in capital. This approach allows investors to participate in the industry's upside while mitigating its risks. The company's recent moves demonstrate its ability to efficiently raise capital, deploy it into high-quality assets, and return profits to shareholders.